https://www.selleckchem.com/products/monastrol.html A 64-year-old female presented to our hospital with a chronic cough. She was diagnosed with cStage ⅢA small cell lung cancer(cT2aN2M0, limited disease). On admission for chemoradiation therapy, laboratory data incidentally revealed liver dysfunction. Further examination resulted in the patient being diagnosed with autoimmune hepatitis. Oral prednisolone therapy was started, and after the improvement of liver function tests, consecutive chemoradiation therapy with cisplatin and etoposide was administered. To the best of our knowledge, this is the first report of a patient with autoimmune hepatitis and small cell lung cancer. Autoimmune hepatitis might arise as a paraneoplastic syndrome.Pancreatic cancer is ranked 4th in Japan in terms of number of deaths so far in 2019, surpassing liver cancer. Unlike other types of cancer, the number of patients in Japan is epidemiologically showing an upward trend, and 70% of cases are unresectable at diagnosis. Therefore, development of chemotherapy that improves the prognosis and maintains and improves the quality of life of the patient is a critical issue. Against this backdrop, the efficacy of nanoliposomal irinotecan(nal-IRI)in combination with fluorouracil and folinic acid(FF)for progressive metastatic pancreatic cancer after previous gemcitabine therapy was confirmed in Europe in 2015 ahead of Japan. In NAPOLI-1, an overseas phase Ⅲ study of this therapy, a significant improvement in overallsurvivalwas shown as compared with patients who received FF alone(median 6.1 months for nal-IRI plus FF vs 4.2 months for FF alone, p=0.012). Therefore, this study yielded important evidence for second-line treatment of pancreatic cancer around the world. In Japan, a phase Ⅱ study was conducted to confirm the efficacy and safety of this therapy, which found a significant prolongation of progression-free survival(as assessed by the investigator)with this therapy as compared with FF alone(